Skip to main content
SpringerLink
Log in

Methotrexate-vindesine association in the treatment of head and neck cancer Influence of vindesine on methotrexate's pharmacokinetic behavior

  • Original Articles
  • MTX+VDS Association, MTX Pharmacokinetics, Head and Neck Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Determination of methotrexate (MTX) kinetics after an IV bolus (50 mg/m2) allows prediction of the steady-state plasma level of this drug during a constant infusion. This prediction allows high-dose MTX (HD-MTX) therapy without major toxicity.

Patients with head and neck carcinoma received HD-MTX and vindesine (VDS) infusions concomitantly. The therapeutic survey of these patients showed that the predicted plasma level of MTX was not achieved in the presence of VDS. Moreover, the computed dose of MTX had to be increased by a larger amount if the MTX plasma clearance after the identification IV push was low (<9 l/h).

In the presence of VDS, the creatinine clearance is lower than when MTX is infused alone, and MTX renal elimination is identical (MTX or MTX+VDS infusions). Thus it seems that the decrease of the MTX plasma level during MTX-VDS infusion could be due to an increase of cellular incorporation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bertino JR, Fischer GA (1964) Technics for study of resistance to folic acid antagonists. Methods Med Res 10: 297

    Google Scholar 

  2. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60: 1128

    Google Scholar 

  3. Cappizi RL, De Conti RC, Marsh JC, Bertino JR (1970) Methotrexate therapy of head and neck cancer: Improvement in therapeutic index by the use of leucovorin “rescue”. Cancer Res 30: 1782

    Google Scholar 

  4. Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52: 1804

    Google Scholar 

  5. Chello PL, Sirotnak FM (1981) Increased schedule-dependent synergism of VDS versus VCR in combination with MTX against L 1210 leukemia. Cancer Treat Rep 65: 1049

    Google Scholar 

  6. Chello PL, Sirotnak FM, Dorick DM (1979) Different effects of vincristine on methotrexate uptake by L 1210 cells and mouse intestinal epithelia in vitro and in vivo. Cancer Res 39: 2106

    Google Scholar 

  7. Cheng E, Young CW, Wittes RE (1980) Phase II trial of vindesine in advanced head and neck cancer. Cancer Treat Rep 64: 1141

    Google Scholar 

  8. Deconti RC, Schoenfeld D (1981) A randomized prospective comparison of intermittent MTX, MTX with leucovorin and a MTX combination in head and neck cancer. Cancer 48: 1061

    Google Scholar 

  9. Favre R, Monjanel S, Alfonsi M, Pradoura JP, Bagarry-Liegey D, Clement S, Imbert AM, Lena N, Colonna d'Istria J, Cano JP, Carcassonne Y (1982) High-dose methotrexate: a clinical and pharmacokinetic evaluation. Cancer Chemother Pharmacol 9: 156

    Google Scholar 

  10. Fyfe MJ, Goldman ID (1973) Characteristics of the vincristine-induced augmentation of methotrexate uptake in Ehrlich ascites tumor cells. J Biol Chem 248: 5067

    Google Scholar 

  11. Fyfe MJ, Lottfield S, Goldman ID (1975) A reduction in energy-dependent amino acid transport by microtubular inhibitors in Ehrlich ascites tumor cells. J Cell Physiol 86: 201

    Google Scholar 

  12. Goldman ID (1981) Membrane transport considerations in high-dose methotrexate regimens with leucovorin rescue. Cancer Treat Rep [Suppl 1] 65: 13

    Google Scholar 

  13. Goldman ID, Gupta V, White JC, Lottfield S (1976) Exchangeable intracellular MTX levels in the presence and absence of VCR at extracellular drug concentrations relevant to those achieved in high dose MTX folinic acid rescue protocols. Cancer Res 36: 276

    Google Scholar 

  14. Imbert AM, Pignon T, Lena N (1983) Methotrexate assay by enzymatic inhibition: comparison between centrifugal analysis (COBAS BIO) and competitive protein-binding assay. Clin Chem (in press)

  15. Levitt M, Mosher MB, De Conti RC et al. (1973) Improved therapeutic index of methotrexate with “Leucovorin rescue”. Cancer Res 33: 1729

    Google Scholar 

  16. Monjanel S, Rigault JP, Cano JP, Carcassonne Y, Favre R (1979) High-dose methotrexate: Preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 3: 189

    Google Scholar 

  17. Sirotnak FM, Donsbach RC (1975) Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors. Cancer Res 35: 1737

    Google Scholar 

  18. Stoller RG, Jacobs SA, Drake JC, Lutz RJ, Chabner BA (1975) Pharmacokinetic of high-dose methotrexate (NSC-740). Cancer Chemother Rep 6: 19

    Google Scholar 

  19. White JC (1981) Recent concepts on the mechanism of action of methotrexate. Cancer Treat Rep [Suppl 1] 65: 3

    Google Scholar 

  20. Young CH (1978) Phase II evaluation of vindesine in patients with advanced cancer. Paper presented at the Sixth Vinca Alkaloid Symposium, London, 20 October 1978

  21. Zager RF, Frisby SA, Oliviero VT (1973) The effects of antibiotics and cancer chemo-therapeutic agents on the cellular transport and antitumor activity of MTX in L 1210 murine leukemia. Cancer Res 33: 1670

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut J. Paoli-I. Calmettes, 232 bd de Ste Marguerite, B.P. 156, Marseille Cedex 9, France

    N. Lena, A. M. Imbert, T. Pignon, R. Favre, G. Meyer, J. P. Cano & Y. Carcassonne

Authors
  1. N. Lena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. M. Imbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Pignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Favre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. P. Cano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y. Carcassonne
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lena, N., Imbert, A.M., Pignon, T. et al. Methotrexate-vindesine association in the treatment of head and neck cancer Influence of vindesine on methotrexate's pharmacokinetic behavior. Cancer Chemother. Pharmacol. 12, 120–124 (1984). https://doi.org/10.1007/BF00254603

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254603

Keywords

Search

Navigation